Why Pharmaceutical Companies Invest in the Cancer biomarker Market
Pharmaceutical companies view the Cancer biomarker Market as critical to drug development. Biomarkers help identify patient populations that respond best to targeted therapies, reducing trial failures and speeding up approvals.
The growing demand for personalized medicine is pushing pharma firms to integrate biomarkers in oncology pipelines. This trend not only improves patient outcomes but also boosts market revenues.
Market Outlook: Valued at USD 15.9 billion in 2022, the cancer biomarker market is forecast to reach USD 27.8 billion by 2030, growing at a 9.8% CAGR.
3 Views